Organigram Replaces Auditor After Adverse Opinion on Internal Controls
Summary
Organigram Global Inc. has replaced its auditor, PKF O'Connor Davies, LLP, with PricewaterhouseCoopers LLP, following an adverse opinion on the company's internal control over financial reporting for the past two fiscal years.
Key Events
-
Auditor Change Announced
Organigram Global Inc. has terminated PKF O'Connor Davies, LLP as its auditor and intends to appoint PricewaterhouseCoopers LLP (PwC) at its next annual general meeting.
-
Adverse Opinion on Internal Controls
The predecessor auditor, PKF O'Connor Davies, LLP, issued an adverse opinion on the effectiveness of the company's internal control over financial reporting for the fiscal years ended September 30, 2025, and September 30, 2024, due to material weaknesses.
-
Unqualified Financial Statements
Despite the adverse opinion on internal controls, the predecessor auditor issued unqualified reports on the company's consolidated financial statements for the fiscal years ended September 30, 2025, and September 30, 2024.
-
No Reportable Events
The company stated there were no 'reportable events' (as defined by National Instrument 51-102) between the Corporation and the Predecessor Auditor.
Analysis
Organigram Global Inc. has changed its auditor from PKF O'Connor Davies, LLP to PricewaterhouseCoopers LLP. This change is significant because the predecessor auditor issued an adverse opinion on the effectiveness of the company's internal control over financial reporting for the fiscal years ended September 30, 2025, and September 30, 2024, due to material weaknesses. While the financial statements themselves received unqualified reports, an adverse opinion on internal controls indicates potential risks in the reliability of financial reporting processes. The appointment of PwC, a 'Big Four' firm, could signal an effort to strengthen financial controls and oversight, but the underlying material weaknesses remain a concern for investors.
At the time of this filing, OGI was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.9M. The 52-week trading range was $0.85 to $2.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.